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ess: jiro@kms.ac.jp (J.Summary Recently, we have experienced significant number of patients diagnosed
with non-specific interstitial pneumonia (NSIP) by open lung biopsy or video-assisted
thoracoscopic surgery. The purpose of this study is to compare clinical and
pathological features of idiopathic NSIP and NSIP associated with underlying diseases
(mainly autoimmune disorders). Forty-six patients with histologically proven NSIP
were retrospectively collected. Twenty-four patients had underlying diseases (12
polymyositis/dermatomyositis, 5 systemic sclerosis, 2 rheumatoid arthritis, 2
Sjogren’s syndrome, 1 ulcerative colitis, 1 primary biliary cirrhosis, and 1 multiple
myeloma). Twenty-two of the 46 patients had no underlying diseases. It was very
difficult to distinguish idiopathic NSIP and NSIP associated with underlying diseases,
clinically and radiologically. Pathologically, lymphocytic pneumonitis was demon-
strated in both groups, and it was impossible to distinguish idiopathic NSIP and NSIP
associated with underlying diseases. Since generalized symptoms were not observed
in patients with idiopathic NSIP, and clinical and pathological features were identical
to NSIP with several autoimmune disorders, we postulate new clinical entities of
‘‘autoimmune interstitial pneumonia’’ in cases without underlying diseases.
r 2004 Elsevier Ltd. All rights reserved.4 Elsevier Ltd. All rights reserved.
-891-2145; fax: +81-87-891-2147.
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In 1994, Katzenstein and Fiorelli reported the
histologic features and clinical significance of
non-specific interstitial pneumonia (NSIP).1 The
histologic features of NSIP include a varying degree
of interstitial inflammation and fibrosis which
appear to develop over a specific time; the process
is temporarily uniform.1 Since then, clinico-patho-
logical features of NSIP have been well-character-
ized.2–17 A recent international consensus report18
defines this entity more specifically, on the basis of
the histopathological appearances of idiopathic
nature, thus distinguishing it from usual interstitial
pneumonia.
More recently, pathological classification of lung
fibrosis has been reevaluated and it has been
reported that the NSIP pattern is frequently
observed in interstitial pneumonia associated with
polymyositis/dermatomyositis,19–22 progressive sys-
temic sclerosis,23–25 and Sjogren’s syndrome.26
However, a significant portion of NSIP is considered
to be unassociated with collagen vascular disorder,
but idiopathic nature.
In the present report, we describe clinical
features of histologically proven idiopathic NSIP
and conclude that idiopathic NSIP should be
considered an ‘‘autoimmune interstitial pneumo-
nia’’ since it was impossible to distinguish idio-
pathic NSIP and NSIP associated with underlying
diseases (mainly autoimmune disorders), clinically
as well as pathologically.Materials and methods
Subjects
Between March 1990 and June 2003, 46 patients
with a pathological diagnosis of NSIP were entered
in this study. No patients had histories of occupa-
tional inhalation of dust or demonstrated digital
clubbing. In auscultatory findings, inspiratory fine
crackles in the back lower lung fields were
observed in all patients. Since, there was no
improvement of symptoms or radiological findings
during the hospital stay, and no antibodies to
Trichosporon cutaneum were demonstrated, we
believe that patients with hypersensitivity pneu-
monitis were not included in our study.
In all patients, high-resolution computed radio-
graphic scanning of the lungs (HRCT) was per-
formed. HRCT was performed by making 12 slices
from above the aortic arch to the diaphragm with
5mm collimation in a bone detail algorithm duringmoderate inspiration. Most subjects underwent
pulmonary function testing before treatment. None
of the patients received immunosuppressive treat-
ment such as corticosteroid or cyclophosphamide at
the time of open lung biopsy. The diagnoses of
interstitial pneumonia were made on clinical,
radiological, physiological, and histological
grounds. In all patients, the diagnosis was made
by means of surgical lung biopsy.
Pathological criteria
All pathologic specimens were analyzed by lung
pathologists (IY and YO) according to the criteria of
NSIP described by Katzenstein and Fiorelli.1 Briefly,
NSIP represented a pattern of chronic interstitial
pneumonia that lacked characteristic features of
other specific entities such as UIP, DIP, hypersensi-
tivity pneumonitis, BOOP, Langerhans’ cell granu-
lomatosis, or chronic eosinophilic pneumonia. Lung
biopsies in this group were characterized by varying
proportions of chronic interstitial inflammation and
fibrosis, which was temporarily uniform. This was in
sharp contrast to the temporarily heterogeneous
pattern of UIP, related in part to an admixture of
recent organization (fibroblastic foci) and old
collagen-rich scars.
Blood samples
Peripheral venous blood samples with and without
ethylenediamine tetraacetic acid (EDTA) were
obtained before breakfast. After centrifugation at
1000g for 10min at 4 1C, the serum was frozen and
stored at 70 1C until used. Arterial blood samples
were analyzed for PaO2 and PaCO2 using a blood gas
analyzer. In serum, we measured C-reactive protein
(CRP), lactate dehydrogenase (LDH), and immuno-
globulin G (IgG). In peripheral venous blood, the
white blood cell numbers (WBC) were measured.
Bronchoalveolar lavage (BAL)
Among 46 patients, BAL was performed in 30
patients. After the upper airway was anesthetized
with topical lidocaine, a flexible fiberoptic
bronchoscope was wedged into the lower respira-
tory tract under visualization. To sample the lower
respiratory tract, BAL was performed by infusing
three 50ml aliquots of sterile saline at the site of
the anterior segment of the right lower lobe. The
last two aliquots were preserved for evaluation.
The fluid was filtered through gauze, and cells were
separated from alveolar lavage fluid by centrifuga-
tion (300g for 10min). BAL fluid (BALF) was frozen
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differentiations and OKT4/OKT8 ratios were mea-
sured.Results
Twenty-two of 46 patients with histologically
proven NSIP had no underlying diseases. Character-
istics of these patients are demonstrated in Table 1.
There were 12 females and 10 males (median age of
61.5). Eighteen patients were diagnosed with NSIP
group II and 4 patients were diagnosed with NSIP
group III according to the Katzenstein’s criteria.1
Although apparent collagen vascular disorders were
not demonstrated, autoantibodies (rheumatoid
factor, anti-nuclear factor, or anti-Jo-1 antibody)
were demonstrated in 6 patients (27.3%).
Twenty-four patients with histologically proven
NSIP had underlying diseases (12 polymyositis/
dermatomyositis, 5 systemic sclerosis, 2 rheuma-
toid arthritis, 2 Sjogren’s syndrome, 1 ulcerative
colitis, 1 primary biliary cirrhosis, and 1 multiple
myeloma). Characteristics of these patients are
demonstrated in Table 2. There were 19 females
and 5 males (median age of 58.5). Autoantibodies
were demonstrated in 19 of 24 patients (79.2%).Table 1 Patient characteristics of idiopathic non-specifi
Case Age and sex Background Autoantibodies
1 69 F () RF*
2 66 M () RF
3 62 F () ()
4 67 F () ()
5 52 M () ()
6 52 F () RF
7 69 M () ANFy
8 66 M () ()
9 77 M () ()
10 51 F () ()
11 55 F () RF, ANF
12 53 F () ()
13 60 F () Jo-1
14 62 M () ()
15 74 M () ()
16 59 M () ()
17 68 F () ()
18 61 F () ()
19 57 M () ()
20 44 F () ()
21 48 F () ()
22 63 M () ()
*Rheumatoid factor.
yAnti-nuclear factor.Table 3 shows the results of laboratory findings,
therapy, and prognosis of 22 patients with second-
ary NSIP. Patients had a relatively high IgG
(177471096mg/dl, mean7standard deviation),
WBC count (801072720/ml), CRP (3.375.5mg/
dl), and LDH (3857138U/l). Their percent vital
capacity (69.4712.8%) and PaO2 (69.4712.8 Torr)
were decreased. In BALF, an increase of lympho-
cytes (30.4729.3%) with an even CD4/CD8 ratio
(1.1071.07) was demonstrated. Steroid therapy
was performed in 18 patients, and steroid plus
cyclophosphamide was administered in 3 patients.
A good response was defined as improvement of
PaO2 and chest CT findings. A poor response was
defined as no improvement of either PaO2 or chest
CT findings. Nineteen of the 22 patients (86.4%)
showed a good response. Poor responses were
experienced in 3 patients. In 3 patients, although
steroid therapy was effective at first, they became
resistant later. Five patients (22.7%) died of
respiratory failure.
Table 4 shows the results of laboratory findings,
therapy, and prognosis of 24 patients with second-
ary NSIP. Patients had a relatively high IgG
(202471245mg/dl, mean7standard deviation),
WBC count (729273075/ml), CRP (1.771.7mg/
dl), and LDH (4887274U/l). Their percent vitalc interstitial pneumonia.
Symptoms at the onset Pathological diagnosis
Cough, dyspnea NSIP (group II)
Cough, fever, dyspnea NSIP (group II)
Cough, dyspnea NSIP (group II)
Cough, fever, dyspnea NSIP (group II)
Cough, dyspnea NSIP (group III)
Cough NSIP (group II)
Cough, dyspnea NSIP (group II)
Cough, fever, dyspnea NSIP (group II)
Dyspnea NSIP (group III)
Cough, fever NSIP (group II)
Cough NSIP (group II)
Cough, fever, dyspnea NSIP (group II)
Cough NSIP (group II)
None NSIP (group II)
Cough, dyspnea NSIP (group III)
Cough, fever, dyspnea NSIP (group II)
Cough, dyspnea NSIP (group III)
Cough, fever, dyspnea NSIP (group II)
Cough, dyspnea NSIP (group II)
Cough, dyspnea NSIP (group II)
Cough, fever NSIP (group II)
Cough NSIP (group II)
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Case Age and sex Background Autoantibodies Symptoms at the onset Pathological diagnosis
1 55 F Dermatomyositis RF*, ANFy, Jo-1 Dyspnea NSIP (group II)
2 44 F Dermatomyositis ANF Fever, dyspnea NSIP (group II)
3 45 F Dermatomyositis ANF Cough, dyspnea NSIP (group II)
4 47 F Dermatomyositis () Cough, dyspnea NSIP (group III)
5 58 M Dermatomyositis () Dyspnea NSIP (group II)
6 70 F Dermatomyositis RF Cough NSIP (group II)
7 69 F Dermatomyositis () Cough, fever NSIP (group II)
8 56 F Polymyositis Jo-1 Dyspnea NSIP (group III)
9 61 F Polymyositis RF, ANF, Jo-1 Cough, dyspnea NSIP (group III)
10 57 M Polymyositis ANF Cough, dyspnea NSIP (group II)
11 62 F Polymyositis Jo-1 Cough, dyspnea NSIP (group II)
12 71 F Polymyositis SS-A Cough NSIP (group II)
13 58 F Systemic sclerosis SCL-70 Cough, fever, dyspnea NSIP (group II)
14 57 F Systemic sclerosis RF Cough, fever, dyspnea NSIP (group II)
15 50 F Systemic sclerosis () Cough, fever, dyspnea NSIP (group II)
16 34 M Systemic sclerosis ANF Dyspnea NSIP (group II)
17 60 F Systemic sclerosis ANF, SCL-70 Cough, dyspnea NSIP (group II)
18 57 F Rheumatoid arthritis RF Cough NSIP (group II)
19 52 F Rheumatoid arthritis RF Cough, dyspnea NSIP (group II)
20 71 F Sjogren’s syndrome SS-A Cough, dyspnea NSIP (group II)
21 59 F Sjogren’s syndrome SS-A Cough, fever NSIP (group II)
22 67 M Ulcerative colitis (-) Cough, dyspnea NSIP (group II)
23 67 F Primary biliary cirrhosis RF, ANF Cough, dyspnea NSIP (group II)
24 74 M Multiple myeloma RF, ANF Dyspnea NSIP (group II)
*Rheumatoid factor.
yAnti-nuclear factor.
Table 3 Laboratory findings, therapy, and prognosis of patients with idiopathic non-specific interstitial
pneumonia.
Case IgG
(mg/dl)
WBC
(/ml)
CRP
(mg/dl)
LDH
(U/l)
PaO2 %VC BAL
(%LYM)
OKT4/
OKT8
Therapy Response Prognosis
1 1847 5000 o0.25 408 67 71.3 40 1.1 Steroid Good Alive
2 2033 8400 12 328 65.7 39.7 8 NA Steroid Good-poor Dead
3 1260 7000 1.7 492 52.9 60.17 80 0.3 Steroid Good Dead
4 5756 10,900 4.7 328 42 62.1 20 0.55 Steroid Good Alive
5 1835.8 8300 0.6 381 91.9 93.3 0 0.08 Steroid Poor Alive
6 1603 7500 o0.25 487 88 56.7 20 0.37 Steroid Good Alive
7 1645 4600 0.1 288 78.8 101.1 5 4.02 Steroid Good Alive
8 1449 10,900 21.7 441 57.2 NA 3 0.65 Steroid Good Alive
9 NA* 15,700 8 426 78.1 60.9 16 0.5 Steroid Good Alive
10 928 6300 0.25 239 74 39.2 47 0.74 Steroid Good Alive
11 1330 4100 1.27 254 72 62.1 NA 1.92 Steroid Good Alive
12 NA 8300 1.2 778 50 47.7 NA NA Steroid Good-poor Dead
13 1430 5400 0.2 410 68 70.1 95 0.29 Steroid Good Alive
14 NA 7790 0.4 220 65.7 91.2 2 3.3 Steroid Good Alive
15 NA 4800 0.2 196 79 93.8 NA NA Steroid Poor Alive
16 1369 8200 1.5 261 70.2 97.4 21 1.91 Steroid+cyclophosphamide Poor Dead
17 1600 7300 0 558 66.5 83 8 1.85 Steroid Good-poor Dead
18 1192 8100 0.4 468 88.1 62.5 71 1.02 Steroid Good Alive
19 NA 11,100 1.5 273 72.4 81.8 57 0.91 Steroid Good Alive
20 1620 10,400 0.2 304 79.6 81.4 15 0.94 Steroid+cyclophosphamide Good Alive
21 NA 6340 4.92 553 53 NA 59 0.31 Steroid+cyclophosphamide Good Alive
22 1480 9800 11.5 376 67.6 57.1 10 0.16 Steroid Good Alive
*Not analyzed.
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Table 4 Laboratory findings, therapy, and prognosis of patients with idiopathic non-specific interstitial
pneumonia.
Case IgG
(mg/dl)
WBC
(/ml)
CRP
(mg/dl)
LDH
(U/l)
PaO2 %VC BAL
(%LYM)
OKT4/
OKT8
Therapy Response Prognosis
1 1495 9600 1.5 1068 68 73.2 NA NA Steroid+cyclophosphamide Good Alive
2 2036 2700 2.1 460 84.3 86.3 21 2.16 Steroid+cyclophosphamide Poor Dead
3 1690 10,800 4.18 318 72 53 16 1.54 Steroid Good Alive
4 1500 3900 0.2 1019 68.4 65.8 53.8 0.002 Steroid+cyclophosphamide Good Alive
5 2200 6000 4.7 695 54.7 NA 82.4 0.66 Steroid+cyclosporin A Poor Dead
6 2640 9000 3.1 839 77.5 45.1 NA NA Steroid+cyclophosphamide Good-poor Dead
7 1350 3200 3.9 480 73.2 76.5 NA NA Steroid Poor Alive
8 1160 11600 0.7 1039 72.1 83.8 NA NA Steroid+cyclophosphamide Good Alive
9 1360 9100 0.3 616 83.9 83.5 NA NA Steroid Good Dead*
10 1210 9200 0.3 576 94.1 51.2 NA NA Steroid+cyclophosphamide Good Alive
11 1430 12,400 0.4 603 85.1 71.4 NA NA Steroid+cyclophosphamide Good Alive
12 NAy 7000 0.4 428 71.5 55.3 NA NA Steroid Good Alive
13 1630 10,900 3.6 266 81 104 6.4 1.8 Steroid Good Alive
14 2300 5600 0 248 98.7 63 6.5 0.8 Steroid Poor Alive
15 1080 1000 NA 478 62 28.7 NA NA Steroid Poor Dead
16 1985 9600 1.19 266 82.1 57.1 NA NA Steroid Poor Alive
17 NA 5100 0.3 233 100 94 NA NA Steroid Poor Alive
18 NA 10000 5.68 174 81 65.3 NA NA Steroid Good Alive
19 2382 6700 1.1 168 76 68.1 1.2 0.71 Steroid Good Alive
20 1780 5500 0.1 506 81.6 60.2 91 0.083 Steroid Good Alive
21 NA 6300 1.1 404 71.6 61.8 20 0.3 Steroid Good Alive
22 2201 9800 2.8 251 74.9 70.8 36 0.7 Steroid Good Alive
23 6960 5000 0.27 287 81 54.2 NA NA Steroid Good Dead*
24 2087 5000 0.1 286 65.2 57.2 15 0.29 Steroid Good Dead*
*Died of other diseases.
yNot analyzed.
J. Fujita et al.238capacity (66.5716.7%) and PaO2 (77.5710.8 Torr)
were decreased. In BALF, an increase of lympho-
cytes (31.8730.9%) with a low CD4/CD8 ratio
(0.8270.71) was demonstrated. Steroid therapy
was performed in 16 patients, steroid plus cyclo-
phosphamide were administered in 7 patients, and
steroid plus cyclosporin A were administered in 1
patient. Seventeen of the 24 patients (70.8%)
showed a good response. Poor responses were
experienced in 7 patients. In 1 patient although
steroid plus cyclophosphamide were effective at
first, the patient became resistant later. Four
patients died of respiratory failure and 3 patients
died of other diseases.
The predominant CT features of NSIP of both
groups were interstitial and patchy parenchymal
opacification in both lungs, predominantly in the
middle and lower lung zones. Scattered ground-
glass opacities were also the most common mani-
festation. Among all patients, neither honeycomb-
ing nor pleural effusions were seen on the initial CT
scan.
We also compared pathological features between
idiopathic NSIP and NSIP with underlying diseases.However, there were no apparent differences
between these 2 groups as previously reported.27,28Discussion
In the present study, we clearly demonstrate the
difficulty of distinguishing idiopathic NSIP and NSIP
associated with collagen vascular disorders, clini-
cally, radiologically, and pathologically.
Although, in several organs, autoimmune inflam-
mation has been well described (for example;
autoimmune thyroiditis, autoimmune hepatitis,
primary biliary cirrhosis, autoimmune pancreati-
tis), there have been no reports about autoimmune
pneumonitis. However, the lung is a large organ
with a huge area directly connected to the atmo-
sphere. In addition, several exogenous materials
such as pathogens (virus, bacteria, and fungi), dust,
chemicals, and organic substances enter the lung
directly. Therefore, it is supposed that antigen
stimulation frequently take place in the lung.
The pathogenesis of NSIP involves injury, an
immune/inflammatory response and fibrosis. In
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bodies were detected in 6 of 22 patients with
idiopathic NSIP. In addition, we have previously
demonstrated that autoantibodies against cytoker-
atin 8 29 cytokeratin 18 30 cytokeratin 19 31 and
vimentin32 are frequently demonstrated in patients
with NSIP. Although the cause of injury is unknown,
frequent identification of serum autoantibodies
makes an autoimmune etiology attractive. Further-
more, since it is well known that NSIP is frequently
associated with autoimmune disorders such as
polymyositis/dermatomyositis,19–22 progressive sys-
temic sclerosis,23–25 and Sjogren’s syndrome,26 it is
possible to speculate that autoimmune etiology
should cause NSIP pattern in the lung. More
importantly, we followed up most patients with
idiopathic NSIP for up to 5 years, with no apparent
collagen vascular disorder, suggesting that inflam-
mation was restricted to the lung and not systemic
nature.
Previously, we reported lymphocyte subsets,
distribution of myofibroblasts, and the appearance
of S-100 positive cells in patients with idiopathic
NSIP.27 Although the distribution of myofibroblasts
differs between idiopathic NSIP and NSIP associated
with collagen vascular disorders,28 it is difficult to
distinguish the histological differences between
these 2 groups.28 In addition, antigen-presenting
cells (S-100 positive cells), frequent autoantibody
formations, and histological evidence of lymphocy-
tic pneumonitis suggest that the autoimmune
process takes place in the pathogenesis of idio-
pathic NSIP.
Based on this evidence, only clinical features of
associated underlying diseases (mainly autoimmune
disorders) distinguished idiopathic NSIP and NSIP
with underlying diseases. In addition, in the
idiopathic NSIP group, there were no apparent
collagen vascular disorders even after long-term
follow-up, suggesting that autoimmune disorder
was restricted only to the lung. Therefore, we
propose that idiopathic NSIP could be considered to
be an ‘‘autoimmune interstitial pneumonia’’.References
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